Analyse Fresenius Medical Care AG & Co KGaA

Fundamental Analysis : FY 2017

Fundamental Analysis : Q1 2017

Rice Powell, Chief Executive Officer of Fresenius Medical Care, stated:


“We saw a very positive start to the year. While both our dialysis services and products business showed strong growth, our Care Coordination activities confirmed its high growth potential. We are shaping our activities in this area and expect the profitability to improve in the course of the year. We are clearly on track to deliver on our ambitious targets for 2017.”


Source : Press Release Fresenius Medical Care AG, May 3, 2017

Fundamental Analysis : FY 2016

Rice Powell, Chief Executive Officer of Fresenius Medical Care, said :
Our revenue reached a new all-time high in 2016: We generated $17.91 billion last year, around 7% more than in 2015. We also set a new record with net income of $1.24 billion, a 21% increase on the previous year. Our success on the stock market is also impressive: At the end of the year, our share price was €80.45, up 3.5% on the start of 2016. 
In the current fiscal year we can propose the highest dividend in our Company’s history at the Annual General Meeting on May 11, 2017. This would be the 20th consecutive dividend increase, from €0.80 in 2015 to the current figure of €0.96 per share, corresponding to a 20% increase.
In 2017, we continue growing strongly in our core business with dialysis products and services as well as expanding our activities in the area of Care Coordination. We expect to generate revenue growth of 8 to 10% on a constant currency basis, as well as a 7 to 9% increase in net income in 2017. 
Over the past 20 years, Fresenius Medical Care’s revenue and dividend have risen consistently. Consistency is exactly what our patients need and expect from us: high-quality products and services, reliability and predictability. After all, our patients trust us with the most important thing they have – their lives.
We keep on applying our knowledge and experience to help patients all over the world. And we also want to enable you, as share- holders, to gain a fair reward from our success, and show that you made the right decision in backing our Company.
I look forward to being able to report back to you next year that with our knowledge and experience, we have become even better and we are working even more efficiently and are continuing to operate successfully worldwide for the good of hundreds of thousands of patients. 
Source : Annual Report Fresenius Medical Care, Bad Homburg v. d. H., March 8, 2017